0000899243-19-017000.txt : 20190614 0000899243-19-017000.hdr.sgml : 20190614 20190614160526 ACCESSION NUMBER: 0000899243-19-017000 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190613 FILED AS OF DATE: 20190614 DATE AS OF CHANGE: 20190614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perkins Adelene Q CENTRAL INDEX KEY: 0001375124 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 19898892 MAIL ADDRESS: STREET 1: C/O INFINITY PHARMACEUTICALS, INC. STREET 2: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 784 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 784 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-13 0 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001375124 Perkins Adelene Q C/O INFINITY PHARMACEUTICALS, INC. 784 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 1 0 0 Chief Executive Officer Stock Option (right to buy) 1.24 2019-06-13 4 A 0 242000 0.00 A 2029-01-03 Common Stock 242000 242000 D This option was approved by the Compensation Committee of the Board of Directors of Infinity Pharmaceuticals, Inc., on January 4, 2019, contingent upon shareholder approval of the Company's 2019 Equity Incentive Plan under which the options were granted, which was approved by shareholders on June 13, 2019. The option vests as to 1/48th of the shares on January 31, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter. /s/ Adelene Q. Perkins 2019-06-13